A once-weekly injectable glucose-dependent insulinotropic polypeptide/GLP-1 dual agonist conferred up to 14.7% weight loss at ...
Anything that helps Americans lose weight, reduces treatment barriers and makes care more affordable should be welcomed. But let's not fool ourselves.
BioArctic AB's (publ) (STO: BIOA B) partner Eisai announced today that the supplemental Biologics License Application (sBLA) for Leqembi Iqlik subcutaneous autoinjector (SC-AI) as a weekly starting ...
At a high level these drugs mimic glucagon-like peptide-1, or GLP-1, a hormone our bodies naturally produce in the gut. When ...
Virginia university leads trial testing ARD-201, an oral drug to maintain weight loss after stopping GLP-1 treatments like ...
A new study led by Mayo Clinic found that postmenopausal women receiving menopausal hormone therapy lost 35% more weight ...
This systematic review evaluates preclinical and clinical evidence on glucagon-like peptide-1 receptor agonists as potential treatments for substance use disorders. Findings show consistent reductions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results